Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide ## Overview Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide is a parasympathomimetic agent that acts as a muscarinic receptor agonist. It is primarily used to increase bladder contraction. ## Primary Indications * Urinary retention (postoperative and postpartum) * Neurogenic bladder dysfunction ## Adult Dosing * **Urinary retention:** 10-20 mg subcutaneously or intramuscularly as a single dose. This dose may be repeated in 15-30 minutes if necessary. The total daily dose should not exceed 50 mg. * **Neurogenic bladder:** Typically 5-10 mg orally three times daily. Dosing is highly individualized and dependent on patient response. ## Pediatric Dosing Safety and efficacy in pediatric patients have not been established. ## Dose Adjustments No specific dose adjustments are routinely recommended for hepatic or renal impairment, but caution should be exercised. ## Contraindications * Hypersensitivity to Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide or its components. * Bradycardia * Hypotension * Uncontrolled asthma * Gastrointestinal or urinary tract obstruction * Parkinsonism * Active peptic ulcer disease * Coronary artery disease * Any condition where increased cholinergic activity would be hazardous. ## Adverse Effects Cholinergic side effects are common and include: * Nausea, vomiting, diarrhea * Abdominal cramps * Increased salivation and sweating * Urinary urgency * Blurred vision * Bradycardia and hypotension ## Key Drug Interactions * **Anticholinergic agents (e.g., atropine, oxybutynin):** May antagonize the effects of Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide. * **Ganglionic blocking agents (e.g., mecamylamine):** May reduce the effects of Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide. * **Other cholinergic agents:** Additive effects, increasing the risk of cholinergic toxicity. ## Monitoring * Monitor for signs of cholinergic overstimulation (e.g., excessive sweating, salivation, bradycardia, hypotension, gastrointestinal upset). * Assess urinary output and bladder function. ## Clinical Pearls * Administer subcutaneously or intramuscularly for acute urinary retention. Oral route is typically for chronic management. * Have anticholinergic agents, such as atropine, readily available to manage overdosage symptoms. * Consider the patient's underlying conditions and potential for cholinergic adverse effects before administration. --- *Disclaimer: This information is intended for clinical decision-making and does not replace a thorough review of the current prescribing information and institutional protocols.*